The global Cell and Gene Solutions Market is experiencing transformative growth, projected to soar significantly between 2025 and 2034. Fueled by cutting-edge advancements in biotechnology, genomics, and the integration of AI/ML, this market is emerging as a cornerstone of modern medicine. The rising incidence of chronic diseases and increasing government and private investments in therapeutic development are accelerating the adoption of cell and gene-based solutions.
North America led the global market in 2024 with an approximate 45% revenue share.
Asia-Pacific is anticipated to register the fastest growth through 2034, driven by increasing biopharmaceutical infrastructure.
Cell therapy solutions dominated by 55% share in 2024.
Gene therapy solutions are forecasted to grow at the fastest CAGR over the forecast period.
The Process Development & Manufacturing segment accounted for nearly 40% of total revenues in 2024.
About: A global CDMO giant headquartered in Switzerland, Lonza provides comprehensive services to the pharmaceutical, biotech, and nutrition sectors.
Products/Services: Cell and gene therapy manufacturing, process development, clinical and commercial supply.
Market Cap: ~$38 billion (as of 2025).
About: U.S.-based Catalent is a leader in enabling cell, gene, and biologics therapies from early development to commercial launch.
Products/Services: Viral vector manufacturing, analytical services, and integrated clinical solutions.
Market Cap: ~$9 billion.
About: A division of WuXi AppTec, WuXi Advanced Therapies offers end-to-end services in gene and cell therapy development.
Products/Services: Viral vector production, cell banking, analytical testing.
Market Cap: WuXi AppTec – ~$20 billion.
About: A global science leader, Thermo Fisher’s Patheon unit offers robust CDMO services including for gene and cell therapies.
Products/Services: Viral vector and plasmid manufacturing, cryogenic logistics.
Market Cap: ~$210 billion.
About: A German biotechnology equipment manufacturer with a strong presence in bioprocessing for cell and gene therapy.
Products/Services: Bioreactors, filtration systems, and analytical tools.
Market Cap: ~$25 billion.
About: Known for pioneering cell separation technologies, Miltenyi Biotec supports cell therapy workflows worldwide.
Products/Services: MACS technology, flow cytometry, clinical-grade reagents.
Market Cap: Privately held (est. revenue ~$800 million+).
About: A U.S.-based provider of preclinical and clinical laboratory services for the pharma and biotech industry.
Products/Services: Viral vector testing, in vivo efficacy studies, cell line characterization.
Market Cap: ~$12 billion.
About: A UK-based advanced therapy company focusing on gene-based medicines, particularly lentiviral vectors.
Products/Services: LentiVector® platform for gene delivery.
Market Cap: ~$400 million.
About: A gene therapy-focused CDMO and therapeutic developer based in the U.S.
Products/Services: End-to-end AAV gene therapy development and manufacturing.
Market Cap: Privately held (series C funding ~$90 million in 2023).
About: South Korea’s leading CDMO with growing influence in gene and cell therapy capabilities.
Products/Services: End-to-end manufacturing, biologics development, and fill-finish services.
Market Cap: ~$50 billion.
About: Spin-off from Nationwide Children’s Hospital, focused on gene therapy.
Products: AAV manufacturing and analytical services.
Market Cap: Privately held (recent funding ~$100 million).
About: A Spanish company specializing in lentiviral vector manufacturing for clinical and commercial use.
Products: Lentiviral vector production for oncology and rare diseases.
Market Cap: Privately held.
About: A contract development and manufacturing organization based in France.
Products: GMP-grade viral vector production and immunotherapies.
Market Cap: Part of Institut Mérieux group.
About: A UK government-supported initiative to industrialize cell and gene therapy in the country.
Products/Services: Non-commercial GMP facilities, regulatory support, innovation enablement.
Market Cap: Publicly funded entity.
Request a customized case study tailored to your business needs and gain deeper insights
into healthcare market strategies: sales@towardshealthcare.com
The market is expected to reach several hundred million USD by 2034, driven by growing demand and technological advancements.
North America currently leads, but Asia-Pacific is projected to witness the fastest growth due to rising healthcare investments.
The surge in rare disease research, advanced genomics, and increased FDA approvals for gene therapies are major growth factors.
Companies like Lonza, Catalent, and Thermo Fisher Scientific dominate this segment by offering scalable manufacturing platforms.
AI is revolutionizing data analysis, therapy design, and manufacturing efficiency, reducing development timelines and enhancing precision.
Source : https://www.towardshealthcare.com/insights/cell-and-gene-solutions-market-sizing
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/price/5902
The global PFAS testing market is experiencing rapid transformation, driven by increasing regulatory scrutiny and public concern over per- and… Read More
Asia-Pacific is poised to become the fastest-growing region in the small-scale bioreactors market over the coming years, driven by several… Read More
North America continues to dominate the global neurostimulation devices market, holding a significant 60% share in 2024. Several key factors… Read More
AAVnerGene Inc., an innovative biotech company based in Rockville, MD, known for its cutting-edge AAV tissue-targeted delivery and manufacturing technologies,… Read More
Jiangsu Hengrui Pharmaceuticals Co., Ltd. and IDEAYA Biosciences, Inc. are set to showcase their groundbreaking research at the IASLC 2025… Read More
QIAGEN has launched its new QIAseq xHYB long-read panels, a cutting-edge solution designed to explore the complexities of genomically diverse… Read More